Community acquired pneumonia (CAP), hospital-acquired pneumonia (HAP) and ventilator associated pneumonia (VAP) are all associated with significant mortality and cause huge expense to health care services around the world. Early, appropriate antimicrobial therapy is crucial for effective treatment. Syndromic diagnostic testing using novel, rapid multiplexed molecular platforms represents a new opportunity for rapidly targeted antimicrobial therapy to improve patient outcomes and facilitate antibiotic stewardship. In this article we review the currently available testing platforms and discuss the potential benefits and pitfalls of rapid testing in pneumonia.

中文翻译：

---

肺炎的快速综合征分子检测：当前的前景和未来的潜力。

社区获得性肺炎（CAP），医院获得性肺炎（HAP）和呼吸机相关性肺炎（VAP）均与高死亡率相关，并给世界各地的医疗服务造成巨额费用。早期，适当的抗微生物治疗对于有效治疗至关重要。使用新颖，快速的多重分子平台进行的综合症诊断测试为快速靶向的抗微生物治疗提供了新的机会，以改善患者的预后并促进抗生素管理。在本文中，我们回顾了当前可用的测试平台，并讨论了在肺炎中进行快速测试的潜在好处和陷阱。